Multiserotype Coxsackievirus B Vaccine Composition With Adjuvant Boosting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines for Coxsackievirus B (CVB) do not effectively induce a robust immune response across multiple serotypes, leaving individuals vulnerable to various diseases caused by this virus.
Innovation Solution
Development of CVB compositions, including inactivated viral particles (IVPs), viral-like particles (VLPs), CVB polypeptides, and nucleic acids encoding these polypeptides, which are administered to induce a broad immune response against one or more CVB serotypes, with specific formulations varying in serotype inclusion and quantity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current CVB vaccines are used, then individuals receive vaccination, but the immune response is not robust and does not effectively protect against multiple serotypes
Solution Approach 1:
The patent creates a universal vaccine composition that can elicit immune responses against multiple CVB serotypes (1-6) simultaneously. The vaccine includes inactivated viral particles from different serotypes and adjuvants that work together to provide broad protective immunity, allowing a single vaccine formulation to protect against various CVB infections rather than requiring separate vaccines for each serotype.
Solution Approach 2:
The patent employs composite vaccine formulations combining inactivated viral particles from multiple serotypes with specific adjuvants (such as AS03, AS04, or MF59). This composite approach synergistically enhances the immune response across different serotypes, creating a more robust and versatile protective effect than individual viral components alone could achieve.
2Object-affected harmful factors
If inactivated viral particles are used in the vaccine composition, then the virus is rendered non-infectious, but the immune response magnitude is reduced compared to live virus vaccines
Solution Approach 1:
The patent introduces adjuvants as intermediary substances that significantly enhance the immune response to inactivated viral particles. The adjuvants (such as AS03 containing QS-21, AS04, or MF59) act as mediators that amplify the antigenic effect of the inactivated virus, enabling the formulation to achieve protective immune levels despite the virus being non-infectious.
Solution Approach 2:
The patent modifies the physical and chemical parameters of the viral particles through inactivation processes (such as formalin or beta-propiolactone treatment) while simultaneously adjusting formulation parameters including adjuvant concentration, particle size, and delivery methods. These parameter changes collectively restore sufficient immune stimulatory capacity to the inactivated virus for effective protection.
Data Source
AI summary
The present disclosure provides coxsackievirus B (CVB) compositions and methods of use of such compositions to induce an immune response to CVB in an individual.